Pelthos Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-43.32	-7.96	-7.38	-2.46	-0.6
Depreciation & Amortization	2.36	-	-	-	-
Other Amortization	0.26	0.69	0.19	0.14	-
Asset Writedown & Restructuring Costs	0.29	-	-	-	-
Stock-Based Compensation	5.46	1.8	1.73	0.11	-
Other Operating Activities	18.44	-0.36	2.43	-	-0.24
Change in Accounts Receivable	-8.81	-	-	-	-
Change in Inventory	1.78	-	-	-	-
Change in Accounts Payable	1.36	1.18	1.63	0.41	-0.83
Change in Unearned Revenue	-0.59	-	-	-	-
Change in Other Net Operating Assets	7.58	-1.14	0.42	0.23	0.07
Operating Cash Flow	-22.59	-5.79	-0.98	-1.57	-1.59
Capital Expenditures	-0.1	-	-	-	-
Cash Acquisitions	-5.14	-	-	-	-
Investing Cash Flow	-5.24	-	-	-	-
Short-Term Debt Issued	0.69	0.54	0.77	0.4	-
Long-Term Debt Issued	17.9	-	-	0.8	1.1
Total Debt Issued	18.59	0.54	0.77	1.2	1.1
Short-Term Debt Repaid	-0.85	-0.22	-	-	-
Total Debt Repaid	-0.85	-0.22	-	-	-
Net Debt Issued (Repaid)	17.75	0.32	0.77	1.2	1.1
Issuance of Common Stock	0.21	6.06	0.26	0.42	0.49
Repurchase of Common Stock	-	-0.08	-	-	-
Other Financing Activities	-	-0.09	-	-	-
Financing Cash Flow	45.34	6.21	1.02	1.62	1.59
Net Cash Flow	17.51	0.42	0.04	0.06	-
Free Cash Flow	-22.69	-5.79	-0.98	-1.57	-1.59
Free Cash Flow Margin	-135.09%	-	-	-	-
Free Cash Flow Per Share	-12.06	-10.39	-7.68	-36.00	-
Cash Interest Paid	0.02	-	-	-	-
Levered Free Cash Flow	-24.65	-6.96	-0.64	-	-
Unlevered Free Cash Flow	-23.03	-7.16	-0.5	-	-
Change in Working Capital	-6.07	0.04	2.05	0.64	-0.76

Updated Mar 19, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q